Brown & Alper 2018: Oral Ibogaine Observational Outcomes in Opioid Use Disorder

Definition box

Definition: Brown & Alper (2018) in *The American Journal of Drug and Alcohol Abuse* (doi: 10.1080/00952990.2017.1320802; PMID 28541119) is a prospective observational study of n=30 adults with DSM-IV opioid dependence treated with oral ibogaine HCl (mean total dose about 1,540 ± 920 mg) in clinic settings. Authors reported acute reductions on the Subjective Opioid Withdrawal Scale (SOWS) and that 50% of subjects reported no opioid use in the prior 30 days at 1-month follow-up, with Addiction Severity Index Composite improvements at later time points. This is not a randomized controlled trial, not FDA approval evidence, and not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine). Cardiac risk—including QTc prolongation—remains central. Most published clinical ibogaine literature is oral. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (57 words)

Brown and Alper’s 2018 observational study of 30 people with opioid dependence found oral ibogaine HCl associated with reduced withdrawal scores and 50% reporting no opioid use in the prior 30 days at one month—not an RCT and not evidence for psychoactive IV ibogaine infusion. Cardiac QTc risk still matters. Ibogaine is not FDA-approved.

Why this paper-spoke exists

Brown & Alper 2018 is one of the most-cited modern oral observational OUD outcome papers. Marketing sometimes turns “50% at one month” into a guaranteed clinic cure rate or into false IV-protocol proof. This spoke keeps numbers in their study design.

Addiction hub: /ibogaine-for-addiction · Oral vs IV: /blog/ibogaine-oral-vs-iv · Entity: /what-is-ibogaine-infusion.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Brown T.K. & Alper K. *Am J Drug Alcohol Abuse*. 2018;44(1):24–36. doi 10.1080/00952990.2017.1320802 | | Design | Observational (prospective detoxification and follow-up outcomes) | | N | 30 (25 male, 5 female) with DSM-IV Opioid Dependence | | Substance patterns | Oxycodone and/or heroin common; substantial prior treatment episodes (mean ~3.1) | | Dose | Mean total oral ibogaine HCl 1,540 ± 920 mg | | Setting | Non-randomized clinic / naturalistic treatment context (as described by authors) | | Primary-style measures | SOWS for acute withdrawal; Addiction Severity Index Composite (ASIC) for follow-up domains | | Follow-up windows | 1, 3, 6, 9, and 12 months |

Methods (plain language)

Adults seeking ibogaine detoxification for opioid dependence were enrolled observationally. They received oral ibogaine HCl at clinic-determined dosing (mean total near 1.54 g). Withdrawal symptoms were scored with SOWS around the treatment window. Drug-use and psychosocial severity composites were tracked for up to a year. There was no placebo arm and no random assignment to alternative evidence-based OUD care as a control.

Plain-language implications:

• Self-selected treatment-seeking samples differ from general clinic populations.
• Self-report of abstinence can overstate success without biochemical verification in every case.
• Attrition and missing long-term data can bias optimistic narratives.
• Interindividual dose and response variability was large (note the ±920 mg SD).

Key findings (no hype)

As reported by the authors:

• SOWS fell from roughly 31.0 ± 11.6 pretreatment to 14.0 ± 9.8 at about 76.5 ± 30 hours posttreatment (statistically significant paired comparison in the paper).
• At 1 month, 15/30 (50%) reported no opioid use in the previous 30 days.
• ASIC Drug Use and certain psychosocial composites improved versus baseline at posttreatment time points; drug-use improvement was maximal at 1 month and partially sustained thereafter (authors note later levels did not reach equivalence to the 1-month peak).

Honest reading: these are meaningful observational signals for a difficult population that had often failed prior treatments. They are hypothesis-generating, not definitive efficacy proof, and not transferable as a branded IV success rate.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Observational / no RCT control | Cannot prove causality vs expectancy, setting, or concurrent supports | | Self-report outcomes | Underreporting of use is possible | | Heterogeneous dosing | Mean ± large SD complicates “the dose” marketing | | Follow-up attrition / variability | Peak 1-month signal may not equal durable abstinence for all | | Setting heterogeneity | Medical monitoring intensity varies across real-world clinics | | Cardiac safety not “solved” by outcome scores | QTc / fatality literature still applies | | Route | Oral — does not validate psychoactive IV |

Compare parallel NZ observational work with an enrolled death discussed honestly: /blog/noller-2018-ibogaine-new-zealand. Larger open-label series: /blog/mash-2018-ibogaine-detox-frontiers.

Route honesty: oral ≠ psychoactive IV

Brown & Alper administered oral ibogaine HCl. That is chemically and pharmacokinetically different from this site’s entity: IV ibogaine infusion as psychoactive intravenous delivery under physician supervision. Oral observational outcomes may inform research interest; they do not prove brand IV protocols.

Support IVs (fluids, magnesium, antiemetics) used in some modern programs are not the same as psychoactive IV ibogaine (/blog/electrolytes-support-iv-vs-psychoactive-iv).

Cardiac / YMYL context

Ibogaine has been associated with QTc prolongation and, in some contexts, fatal arrhythmias. Knuijver et al. (*Addiction* 2021) documented clinically relevant QTc prolongation after oral 10 mg/kg in a monitored university setting. Systematic reviews (Köck 2022; Mosca 2023) flag cardiotoxicity and mortality concerns alongside withdrawal/craving signals.

Anyone considering any ibogaine exposure needs ECG/electrolyte diligence and continuous monitoring culture—not outcome-statistic shopping (/safety-and-screening, /blog/ibogaine-ecg-pre-infusion-checklist, /blog/ibogaine-mortality-cardiac-risk).

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “50% cure rate for IV ibogaine” | False — oral observational; 1-month self-report subset metric | | “RCT-proven OUD treatment” | False — observational | | “FDA-cleared detox” | False — Schedule I; not FDA-approved | | “Safe because SOWS improved” | False — efficacy-ish scores ≠ cardiac safety proof | | Cite as adjacent oral literature with labels? | Yes — if design/route/N labeled |

U.S. access context remains Schedule I / not FDA. Provisional Mexico programs on this site ≠ U.S. FDA clinics (/blog/is-ibogaine-legal-us, /blog/ibogaine-mexico-medical-vs-tourism).

Soft CTA

If Brown & Alper numbers prompted interest in physician-supervised IV ibogaine infusion, begin with cardiac and evidence-gap literacy: /safety-and-screening. Then request a confidential screening consult via /apply—not after “50% cured” marketing.

FAQ

What did Brown & Alper 2018 study? Observational outcomes after oral ibogaine HCl in 30 people with opioid dependence, including SOWS and ASI composites.

What dose was used? Mean total oral ibogaine HCl about 1,540 mg (±920 mg)—high variability.

What does the 50% figure mean? At 1 month, 15 of 30 reported no opioid use in the prior 30 days—not a lifetime cure rate and not an IV RCT endpoint.

Was this a randomized controlled trial? No. Observational design without a randomized control arm.

Does this prove IV ibogaine infusion works? No. Route was oral; design was observational.

Are cardiac risks irrelevant because withdrawal scores fell? No. Cardiac QTc risk must be evaluated separately (/safety-and-screening).

Is ibogaine FDA-approved for OUD? No. Schedule I in the U.S.; not FDA-approved.

Where can I read adjacent oral OUD papers? /blog/noller-2018-ibogaine-new-zealand, /blog/mash-2018-ibogaine-detox-frontiers, /blog/kock-2022-ibogaine-systematic-review.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Brown & Alper 2018 is oral observational OUD literature—not psychoactive IV ibogaine proof.

Sources (selected)

1. Brown T.K., Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. *Am J Drug Alcohol Abuse*. 2018. doi: 10.1080/00952990.2017.1320802. PMID: 28541119.
2. Noller G.E. et al. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. *Am J Drug Alcohol Abuse*. 2018. doi: 10.1080/00952990.2017.1310218.
3. Mash D.C. et al. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. *Front Pharmacol*. 2018. doi: 10.3389/fphar.2018.00529.
4. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
5. Köck P. et al. *J Subst Abuse Treat*. 2022. doi: 10.1016/j.jsat.2021.108717.
6. 21 CFR 1308.11 — ibogaine Schedule I (United States).